(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 00157) Dear non-registered shareholder(s), 16 March 2026 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 With reference to the notification letter dated 9 February 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Natural Beauty Bio-Technology Limited (the "Company") is writing to re ...

自然美生物科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 00157) Dear registered shareholder(s), Natural Beauty Bio-Technology Limited 16 March 2026 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (Note 1) With reference to the notification letter dated 9 February 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Natural Beauty Bio-Technology Limited (the "Company") is writing ...

Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 （於開曼群島註冊成立之有限公司） 前 言 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）已 修 訂 企 業 管 治 的 準 則，以 進 一 步 提 升 香 港 發 行 人 企 業 管 治 的 整 體 水 平。其 主 要 變 化 包 括：《聯 交 所 證 券 上 市 規 則》（「上 市 規 則」）不 時 更 新 的 附 錄C1中 企 業 管 治 守 則 的 修 訂（「該守則」）。 審 核 委 員 會 乃 本 公 司 董 事 會（「董事會」）委 任，以 協 助 董 事 會 履 行 其 監 督(1)本 公 司的財務報表的完整性、監控和信息披露；(2)本公司對法律和監管要求的遵守； (3)本公司外聘核數師的資格和獨立性；及(4)本公司的內部審核職能及其外聘核 數師的表現，以及風險管理及內部監控系統的有效性。 如審核委員會憲章之中英文版本有任何歧義，概以英文版本為準。 該守則的原則 （「本公司」） 審核委員會憲章 （本公司依據2026年3月9日通過的董事會決議案修訂及採納， 並 於2026年3月10日起生效） ...

Financial Performance - Revenue for FY2025 reached HK$538,831,000, representing a 52.5% increase from FY2024's revenue of HK$353,651,000[23] - Gross profit for FY2025 was HK$293,342,000, up from HK$202,330,000 in FY2024, indicating a gross profit margin improvement[23] - Operating profit for FY2025 was HK$23,180,000, a significant recovery from an operating loss of HK$97,162,000 in FY2024[23] - The net profit for FY2025 was HK$10,581,000, compared to a net loss of HK$103,615,000 in FY2024, marking a turnaround in profitability[23] - The return on equity (ROE) for FY2025 was 2.2%, recovering from a negative ROE of (23.1%) in FY2024[23] - The basic earnings per share for FY2025 was HK$0.0053, a recovery from a loss per share of HK$0.0518 in FY2024[23] - The Group's net profit for 2025 is approximately HK$10.6 million, a significant recovery from a net loss of approximately HK$103.6 million in 2024[70][74] Revenue Breakdown - The breakdown of turnover by activities shows 66.0% from conventional products, 32.6% from beauty apparatus, and 1.4% from services[26] - The Group's revenue increased by 52.4% to HK$538.8 million in 2025, up from HK$353.7 million in 2024, primarily driven by a HK$180.7 million increase in product sales, which accounted for 98.6% of total revenue[32][35] - Revenue in the PRC market rose by 74.7% to HK$445.8 million in 2025, compared to HK$255.2 million in 2024, largely due to increased sales of beauty apparatus[33][44] - Revenue from the Taiwan market decreased by 2.6% to HK$89.7 million in 2025, down from HK$92.1 million in 2024, attributed to a cautious economic outlook[33][45] - Revenue from other regions, including Hong Kong and Malaysia, fell by 48.4% to HK$3.3 million in 2025, contributing only 0.6% to the Group's total revenue[33][34] Cost and Expenses - The cost of sales for FY2025 was HK$245,489,000, which is an increase from HK$151,321,000 in FY2024, indicating rising costs associated with increased revenue[23] - Total administrative expenses decreased by HK$8.6 million to HK$71.8 million in 2025, with significant components including staff costs of HK$33 million and consultancy fees of HK$10.8 million[52] - Distribution and selling expenses as a percentage of revenue decreased from 48.4% in 2024 to 37.2% in 2025, despite an increase in total distribution and selling expenses to HK$200.3 million[51] Market Performance - Sales of beauty apparatus surged by 504.7% to HK$175.8 million in 2025, compared to HK$29.1 million in 2024, making up 32.6% of total revenue[38][41] - Service income increased by 137.0% to HK$7.7 million in 2025, up from HK$3.3 million in 2024, driven by self-owned spas[40][43] - Total revenue from the PRC market rose by 74.7% to HK$445.8 million in 2025, driven by a 73.4% increase in product sales and a 208.9% increase in service revenue[49] Strategic Initiatives - The Group launched new product lines, including "Crystal Peptide & Health Food" and the INDIBA Moonlight beauty device, enhancing its product portfolio[96] - The Group is leveraging AI technology across the entire supply chain, aiming to build an authoritative AI skin health detection platform trained on millions of samples[115] - The Group implemented a "One Product, One Code" traceability system in collaboration with Fudan University, enhancing transparency and management standards[97] - The Group's strategic partnership with Fudan University aims to establish a transparent management standard through a traceability system[101] Governance and Compliance - The Board of Directors consists of eight members, including three executive directors, two non-executive directors, and three independent non-executive directors[137] - The Company has adopted a code of conduct for securities transactions that meets or exceeds the standards set out in the Model Code, with no reported incidents of non-compliance for the year ended December 31, 2025[153][154] - The Company allows directors to seek independent professional advice at its expense, ensuring informed decision-making[151] - The Company has established guidelines for securities transactions by relevant employees, ensuring adherence to compliance standards[154]

Financial Performance - The company reported a consolidated revenue of HKD 1.2 billion for the fiscal year ending December 31, 2025, representing a year-on-year increase of 15%[19]. - The net profit for the same period was HKD 300 million, reflecting a growth of 20% compared to the previous year[19]. - Future guidance estimates a revenue growth of 12% for 2026, projecting total revenue to reach HKD 1.34 billion[19]. - The Group's revenue for 2025 increased by 52.4% to HK$538.8 million compared to HK$353.7 million in 2024, primarily driven by a HK$180.7 million increase in product sales, which accounted for 98.6% of total revenue[29]. - The Group's net profit for 2025 was approximately HK$10.6 million, a significant recovery from a net loss of approximately HK$103.6 million in 2024[67][71]. User Growth and Market Expansion - User data indicated a 25% increase in active users, reaching 1.5 million by the end of 2025[19]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2026[19]. - The Taiwan market is advancing a dual-track strategy of "multi-channel marketing" and "high-repurchase products," optimizing profit models and strengthening terminal competitiveness[117]. Product Development and Innovation - Research and development expenses increased by 30% to HKD 150 million, focusing on innovative beauty technologies[19]. - The company plans to launch two new product lines in Q2 2026, aiming to capture an additional 10% market share in the beauty sector[19]. - The introduction of AI-assisted data analysis tools in R&D processes improved development efficiency and product quality consistency[100]. - The Company plans to build an authoritative AI skin health detection platform trained on millions of samples to provide precise skincare solutions[112]. Sales and Revenue Channels - Sales revenue from TV shopping, E-commerce, and telemarketing channels in Taiwan contributed HK$25.6 million, accounting for 28.6% of product sales in the region[43][46]. - In 2025, the Group achieved HK$497.8 million in sales from franchised/self-owned spas, medical cosmetology centers, and counters, an increase of HK$182.0 million from HK$315.8 million in 2024, representing 92.4% of total revenue[83]. - Sales from e-commerce, TV shopping, and telemarketing channels reached HK$41.0 million, up by HK$3.2 million from HK$37.8 million in 2024, accounting for 7.6% of total revenue[84]. Cost and Expense Management - Distribution and selling expenses increased by HK$29.3 million to HK$200.3 million in 2025, but as a percentage of revenue, they decreased to 37.2% from 48.4% in 2024[48][54]. - Total administrative expenses decreased by HK$8.6 million to HK$71.8 million in 2025, with major components including staff costs and consultancy fees[49][54]. Corporate Governance - The Board consists of eight members: three Executive Directors, two Non-executive Directors, and three Independent Non-executive Directors[134]. - The Company has adopted a code of conduct for Directors' securities transactions, compliant with the Model Code, with no reported incidents of non-compliance for the year ended December 31, 2025[150]. - The Company has established stringent guidelines for relevant employees regarding securities transactions, with no incidents of non-compliance noted[151]. - The Company has established a Board Independence Evaluation Mechanism to ensure strong independent judgment and safeguard shareholders' interests[164]. Strategic Partnerships and Collaborations - A strategic partnership with Gideon Education Group led to the launch of five "Bio-up" Biotech Aesthetic SPA Centers in Xi'an, Shanghai, and Nanchang in 2025[95]. - The Group's flagship NB-1 Crystal Peptide Series underwent a comprehensive upgrade, integrating multiple active ingredients and intelligent delivery systems[101]. Operational Efficiency and Technology Integration - The Fengxian Smart Factory is set to enhance operational efficiency and profitability through the integration of industrial robots, AGV systems, and AI vision technology[111]. - The company aims to enhance operational efficiency and profitability through the integration of AI technologies in its manufacturing processes[115]. Financial Position and Assets - Total assets for the Group were HK$925.6 million in 2025, with a net asset value of HK$473.98 million[20]. - The Group's gearing ratio increased from 43.0% in 2024 to 62.2% in 2025, indicating a higher level of debt relative to equity[69][73]. - As of December 31, 2025, the Group had cash and cash equivalents of approximately HK$104.3 million, down from HK$109.0 million as of December 31, 2024[68][72]. Franchise and Store Operations - The Group opened 440 new stores in 2025, compared to 324 in 2024, while closing 127 stores, up from 106 in the previous year[88]. - As of December 31, 2025, the Group operated a total of 2,080 spas or points of sales, including 2,070 franchised locations and 10 directly operated spas, with 13 concessionary counters[87]. Employee and Talent Management - The Group's total remuneration in 2025 was approximately HK$163.9 million, up from HK$148.4 million in 2024[104]. - The 2025 stock option plan aims to recognize contributions from eligible participants and attract suitable talent for further development[80].

2025 Environmental, Social and Governance Report 環境、社會及管治報告 Mission Statement Natural Beauty is dedicated to cultivate our staff, customers, students and franchisees to appreciate our education, products and services, which are the mission and belief of the brand and to make modern ladies beautiful, confident and wealthy. 我們致力於使員工、顧客、學員及加盟老師們存著一份感恩的心來到自然美，學習自 然美容術及使用自然美產品及服務，這都是東森自然美這個品牌一直以來的使命與信 念，幫助無數女性建立美麗、自信及財富。 Contents | About the Report | | --- | | 關於本報告 2 | | Reporting Period | | 報告期 2 | | Reporting ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 公司名稱: 自然美生物科技有限公司（根據開曼群島法例註冊成立的有限公司） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00157 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0 ...

格隆汇2月13日丨自然美(00157.HK)发布公告，谨定于2026年3月9日(星期一)举行董事会会议，以考虑 及通过本集团截至2025年12月31日止年度全年业绩，及建议的末期股息(如有)，以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Natural Beauty Bio-Technology Limited 自然美生物科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號：00157） 自 然 美 生 物 科 技 有 限 公 司（「本公司」及 其 附 屬 公 司「本集團」）董 事 會（「董事會」） 茲 通 告 謹 定 於 二 零 二 六 年 三 月 九 日（星 期 一）舉 行 董 事 會 會 議，以 考 慮 及 通 過 本 集團截至二零二五年十二月三十一日止年度全年業績，及建議之末期股息（如有）， 以及處理其他事項。 承董事會命 自然美生物科技有限公司 雷 倩 主 席 香港，二零二六年二月十三日 於本公告日期，董事會由執行董事雷倩博士、林家偉先生及林燕玲女士；非執行 董 事 林 淑 華 女 士 及 陳 守 煌 先 生；以 及 獨 立 非 執 行 董 事 陳 瑞 隆 先 生、林 蒼 祥 先 生 及楊世緘先生組成。 董事會召開日期 ...

I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00157 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.1 HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 自然美生物科技有限公司（根據開曼群島法 ...